Table 2.
Characteristics of studies reporting vascular access parameters associated with filter life [17, 19–50, 103]
| Study Name | Sample Size | Design | Description | Inclusion Criteria | Exclusion Criteria | Intervention/Comparison | Control |
|---|---|---|---|---|---|---|---|
| du Cheyron et al., 2006 [35] | 78 patients/193 filters | Retrospective Cohort | Antithrombin administration vs Heparin | Septic shock, CRRT, 1/2001 to 12/2004 | Antithrombin cutoff parameters | Antithrombin administration | Regional Heparin |
| Kim et al. 2011(b) [92] | 50 patients/341 circuits | Prospective Observational | Niagara vs Dolphin Catheters for CRRT | CRRT with femoral access | N/A | Niagara 13.5Fr | Controlling for other variables |
| Kim et al. 2011 [37] | 50 patients/341 circuits | Prospective Observational | Insertion side, body position and circuit life | CRRT with femoral access | N/A | Anticoagulation | Controlling for other variables |
| Chua et al., 2012 [50] | 71 patients/539 filters | Retrospective Cohort | Circuit Life in Hepatic Failure with AKI | Age > 18 years, Hepatic Failure, AKI, January 2006 to July 2011 | N/A | Multivariate Analysis | Heparin |
| Morgan et al. 2012 [26] | 100 patients/400 filters | Randomised Unblinded Controlled Trial | Catheter Length in CRRT | Upper body catheter, short term CRRT | exist long term catheter, indication for femoral access, systemic anticoagulation, citrate for excess bleeding risk | 13.5 Fr Longer Catheter Length | Controlling for other variables |
| Fealy et al. 2013 [93] | 46 patients/254 filters | Prospective Cohort | Comparison of Niagara & Medcomp catheters | CVVH Exposure | IHD | Medcomp 13.5Fr 24 cm O-O | Niagara 13.5Fr 24 cm D-D |
| Hwang et al., 2013[60] | 222 patients/1236 filters | Retrospective Cohort | Nefamostat vs Heparin | CRRT treated patients 1/2004 to 12/2008 | deceased within first filter use, paraquat poisoning | APTT (sec) | Controlling for other variables |
| Mottes et al., 2013 [38] | 80 patients/343 filters | Prospective Observational | Process Control Analysis through changing model of care and education | CRRT 7/2007 to 7/2010 | N/A | ICU Nurse CRRT and simulation | No Anticoagulation |
| Brain et al. 2014 [27] | 30 patients/221 Filters | Post-hoc analysis of RCT | Citrate vs Heparin | CRRT, AKI criteria | Weight, contra-indication to study arm, pregnancy, previous CRRT, hypothermia, specific mode CRRT | Citrate Anticoagulation | Dolphin 13.5Fr |
| Crosswell at al. 2014 [24] | 131 patients/870 filters | Retrospective Cohort | Circuit Life by Vascular Access Site | CRRT, Vascular Access Data | N/A | Vascular Access Site Comparison | 13.5 Fr Shorter Catheter Length |
| Dunn & Sriram, 2014 [23] | 355 patients/1332 filters | Retrospective Cohort | Patient and Treatment Variables on Filter Life | CRRT 1/2008 to 8/2011 | N/A | Multivariate Analysis | Nephrology nurse run CRRT |
| Sponholz et al., 2014 [94] | 1621 patients/10643 filters | Retrospective Cohort | Anticoagulation strategies over 5 year period | CRRT, 1/2007 to 12/2012 | N/A | Femoral Access | Non-Femoral Access |
| Wang et al. 2014 [36] | 34 patients/126 filters | Prospective Cohort Study | Effect of mobilisation on filter life | CRRT, 8/2011 to 8/2012, temporary vascular access | Permanent vascular access, SLED | Mobilisation | Baseline |
| Zhang et al., 2015 [39] | 23 patients/79 filters | Prospective Observational | Patterns and Mechanisms of artificial kidney failure | Age > 18 years, CRRT, Prismaflex | Non-prismaflex machine, plasma exchange, CRRT duration <24 hours | Stratify filter failure by access pressure | Controlling for other variables |